Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


123456>>>
127 Items
Title  Creator  Group name  Publishing year 
Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe. Tabet et al. EquipeCTCS 2025
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer Bardia et al. EquipeCTCS 2024-12-05
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features Boissière-Michot et al. EquipeCTCS 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer Massa et al. EquipeCTCS 2024-12-01
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients Puszkiel et al. EquipeCTCS 2024-08-01
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort Galvin et al. EquipeCTCS 2024-01
First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study Bardol et al. EquipeCTCS 2024-01
Efficacy of a physiotherapy, yoga and patient education programme for patients with breast cancer and hormone therapy-induced pain: a multicentre randomised study protocol (SKYPE 2) Faravel et al. EquipeCTCS 2024-01-08
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer Eslami-S et al. EquipeCTCS 2024-01
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer Orhan et al. EquipeCTCS 2024-05-01
Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation Antoine et al. EquipeCTCS 2024-12
[Therapeutic advances in HER2+ breast cancer] Alexandre and Jacot EquipeCTCS 2023-04
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hurvitz et al. EquipeCTCS 2023-01-14
The quest for the optimal biomarker: is extending the spectrum of targeted PIK3CA mutations in breast cancer carcinoma worthwhile? Quesada and Jacot EquipeCTCS 2023-10-25
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database Mailliez et al. EquipeCTCS 2023-03-01
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2023-02-02
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program Le Du et al. EquipeCTCS 2023-10-03
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort Grinda et al. EquipeCTCS 2023-08
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients Griguolo et al. EquipeCTCS 2023-09-15
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases Bottosso et al. EquipeCTCS 2023-03
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer Glaviano et al. EquipeCTCS 2023-08-18
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial Bidard et al. EquipeCTCS 2023-11-06
NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells Campos-Mora et al. EquipeCTCS 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers Hutchinson et al. EquipeCTCS 2023-04-26
Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer Sinoquet et al. EquipeCTCS 2023-01-04
123456>>>
127 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés